Lanean...

Future of targeted agents in metastatic colorectal cancer

Great strides have been made in improving the outcome of patients with metastatic colorectal cancer and targeted agents are an important part of the treatment arsenal. The approved monoclonal antibodies, bevacizumab, cetuximab and panitumumab, are part of the standard of care, yet only recently have...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Burotto, Mauricio, Hartley, Marion L, Marshall, John L, Pishvaian, Michael J
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3834580/
https://ncbi.nlm.nih.gov/pubmed/24273599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/crc.12.52
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!